Latest News and Press Releases

Ethics Committee approval to proceed with Phase 3 clinical trial in Turkey13 clinical sites selected to date in Turkey TORONTO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive”...

701 subjects dosed to dateInitiating enrollment activities in Turkey as part of its clinical diversification plans to support global regulatory approvals On-track to complete enrollment in Q1-2022 and...

IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 ...

Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 ...

Screened approximately 700 subjects and expanding to Eastern Europe, including Turkey, as part of its clinical diversification plans to support global regulatory approvalsNo serious adverse events and...

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding...

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding...

TORONTO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...

TORONTO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...

Building specialty psilocybin-based product pipeline Evaluating potential for neuropsychiatric indications for clinical studies in 2022 TORONTO, Nov. 03, 2021 (GLOBE NEWSWIRE) --...